Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 32.27
VSTM's Cash-to-Debt is ranked higher than
79% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. VSTM: 32.27 )
Ranked among companies with meaningful Cash-to-Debt only.
VSTM' s Cash-to-Debt Range Over the Past 10 Years
Min: 32.27  Med: No Debt Max: No Debt
Current: 32.27
Piotroski F-Score: 1
Altman Z-Score: -1.90
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -51.41
VSTM's ROE % is ranked lower than
54% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. VSTM: -51.41 )
Ranked among companies with meaningful ROE % only.
VSTM' s ROE % Range Over the Past 10 Years
Min: -82.34  Med: -51.76 Max: -39.63
Current: -51.41
-82.34
-39.63
ROA % -46.04
VSTM's ROA % is ranked lower than
57% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. VSTM: -46.04 )
Ranked among companies with meaningful ROA % only.
VSTM' s ROA % Range Over the Past 10 Years
Min: -54.66  Med: -39.94 Max: -23.18
Current: -46.04
-54.66
-23.18
ROC (Joel Greenblatt) % -2647.20
VSTM's ROC (Joel Greenblatt) % is ranked lower than
72% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. VSTM: -2647.20 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
VSTM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -5742.3  Med: -2745.45 Max: -1932.02
Current: -2647.2
-5742.3
-1932.02
3-Year EBITDA Growth Rate -18.50
VSTM's 3-Year EBITDA Growth Rate is ranked lower than
73% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. VSTM: -18.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
VSTM' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -41.9  Med: -18.5 Max: -2.2
Current: -18.5
-41.9
-2.2
3-Year EPS without NRI Growth Rate -18.40
VSTM's 3-Year EPS without NRI Growth Rate is ranked lower than
70% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. VSTM: -18.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
VSTM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -42  Med: -18.4 Max: -1.8
Current: -18.4
-42
-1.8
GuruFocus has detected 3 Warning Signs with Verastem Inc $VSTM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» VSTM's 30-Y Financials

Financials (Next Earnings Date: 2017-08-08 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

VSTM Guru Trades in Q2 2016

Jim Simons 634,900 sh (+38.79%)
» More
Q3 2016

VSTM Guru Trades in Q3 2016

Jim Simons 899,600 sh (+41.69%)
» More
Q4 2016

VSTM Guru Trades in Q4 2016

Jim Simons 1,022,200 sh (+13.63%)
» More
Q1 2017

VSTM Guru Trades in Q1 2017

Jim Simons 1,226,600 sh (+20.00%)
» More
» Details

Insider Trades

Latest Guru Trades with VSTM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:VCEL, NAS:AGLE, NAS:OPHT, NAS:AKTX, OTCPK:PTGEF, NAS:ARQL, NAS:INFI, NAS:NEPT, OTCPK:MCUJF, OTCPK:RNUGF, NAS:MRTX, OTCPK:MTFBF, OTCPK:ORGS, NAS:LIFE, NAS:BLRX, AMEX:ATNM, NAS:NOVN, NAS:SVRA, NAS:NTEC, NAS:AVEO » details
Traded in other countries:2VS.Germany,
Headquarter Location:USA
Verastem Inc is a biopharmaceutical company engaged in discovering and developing drugs to improve outcomes for patients with cancer. Its product candidates include duvelisib and defactinib (VS-6063).

Verastem Inc incorporated under the laws of the State of Delaware in August 2010. It is a is a biopharmaceutical company. The Company is engaged discovering and developing drugs to improve outcomes for patients with cancer. Its product candidates, duvelisib and defactinib (VS-6063), utilize a multi-faceted approach to treat cancers originating either in the blood or organ systems. The Company is evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. It faces competition from pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions.

Ratios

vs
industry
vs
history
PB Ratio 1.46
VSTM's PB Ratio is ranked higher than
90% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. VSTM: 1.46 )
Ranked among companies with meaningful PB Ratio only.
VSTM' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.52
Current: 1.46
0
1.52
EV-to-EBIT -0.41
VSTM's EV-to-EBIT is ranked higher than
97% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. VSTM: -0.41 )
Ranked among companies with meaningful EV-to-EBIT only.
VSTM' s EV-to-EBIT Range Over the Past 10 Years
Min: -0.52  Med: 0 Max: 1.09
Current: -0.41
-0.52
1.09
EV-to-EBITDA -0.41
VSTM's EV-to-EBITDA is ranked higher than
97% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. VSTM: -0.41 )
Ranked among companies with meaningful EV-to-EBITDA only.
VSTM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.52  Med: 0 Max: 1.11
Current: -0.41
-0.52
1.11
Current Ratio 5.59
VSTM's Current Ratio is ranked higher than
70% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. VSTM: 5.59 )
Ranked among companies with meaningful Current Ratio only.
VSTM' s Current Ratio Range Over the Past 10 Years
Min: 5.59  Med: 14.04 Max: 30.79
Current: 5.59
5.59
30.79
Quick Ratio 5.59
VSTM's Quick Ratio is ranked higher than
70% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. VSTM: 5.59 )
Ranked among companies with meaningful Quick Ratio only.
VSTM' s Quick Ratio Range Over the Past 10 Years
Min: 5.59  Med: 14.04 Max: 30.79
Current: 5.59
5.59
30.79

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -13.50
VSTM's 3-Year Average Share Buyback Ratio is ranked lower than
58% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. VSTM: -13.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
VSTM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -176.1  Med: -22 Max: -13.5
Current: -13.5
-176.1
-13.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.54
VSTM's Price-to-Net-Cash is ranked higher than
96% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. VSTM: 1.54 )
Ranked among companies with meaningful Price-to-Net-Cash only.
VSTM' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0  Med: 2.9 Max: 5.77
Current: 1.54
0
5.77
Price-to-Net-Current-Asset-Value 1.51
VSTM's Price-to-Net-Current-Asset-Value is ranked higher than
96% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. VSTM: 1.51 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
VSTM' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0  Med: 2.84 Max: 5.7
Current: 1.51
0
5.7
Price-to-Tangible-Book 1.45
VSTM's Price-to-Tangible-Book is ranked higher than
93% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. VSTM: 1.45 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
VSTM' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.54  Med: 2.16 Max: 3.86
Current: 1.45
0.54
3.86
Earnings Yield (Greenblatt) % -237.50
VSTM's Earnings Yield (Greenblatt) % is ranked higher than
99% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. VSTM: -237.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
VSTM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -32342.25  Med: 0 Max: 14220.48
Current: -237.5
-32342.25
14220.48

More Statistics

EPS (TTM) $ -1.11
Beta3.03
Short Percentage of Float0.66%
52-Week Range $1.05 - 2.54
Shares Outstanding (Mil)36.99

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 4 53
EPS ($) -1.32 -1.63 -0.79
EPS without NRI ($) -1.32 -1.63 -0.79
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for VSTM

Headlines

Articles On GuruFocus.com
BioXcel Therapeutics, Inc. (BTI) Is Launched with Phase 2-ready Programs Addressing Unmet Needs in I May 10 2017 
5 of the Most Discounted U.S. Listed Net-Nets Mar 30 2016 
5 Deep Value or Net-Net Investment Ideas Feb 09 2016 

More From Other Websites
Verastem Announces Duvelisib Data Presentations at the 22nd Congress of the European Hematology... May 18 2017
Today's Research Reports on Stocks to Watch: Array Biopharma and Verastem May 11 2017
Verastem reports 1Q loss May 10 2017
Verastem Reports First Quarter 2017 Financial Results May 10 2017
BioXcel Therapeutics, Inc. (BTI) Is Launched with Phase 2-ready Programs Addressing Unmet Needs in... May 10 2017
Verastem Announces Long Term Follow-up Data from the DYNAMO Study Selected for Oral Presentation at... May 03 2017
Verastem Appoints Eric K. Rowinsky to the Board of Directors May 02 2017
Today's Research Reports on Biotech Stocks to Watch: Ocera Therapeutics and Verastem Apr 17 2017
Verastem to Present at the 16th Annual Needham Healthcare Conference Apr 03 2017
Data on Verastem’s Focal Adhesion Kinase Inhibitor Defactinib Presented at the 2017 American... Apr 02 2017
Verastem Reports Year-End 2016 Financial Results Mar 23 2017
Verastem to Host Conference Call on March 23rd to Discuss Fourth Quarter and Full-Year 2016... Mar 16 2017
Verastem to Present at the Oppenheimer 27th Annual Healthcare Conference Mar 15 2017
Verastem to Present at the 29th Annual ROTH Conference Mar 07 2017
Verastem to Present at 19th Annual BIO CEO & Investor Conference Feb 07 2017
Verastem Announces Dosing of First Patient in Combination Trial of Defactinib and Avelumab in... Jan 26 2017
Verastem Announces Executive Leadership Appointments and Changes Jan 19 2017
Verastem's CEO Talks DYNAMO Study, The Competitive Landscape And Pitch To Investors Jan 19 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)